[go: up one dir, main page]

MXPA03010350A - Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar. - Google Patents

Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar.

Info

Publication number
MXPA03010350A
MXPA03010350A MXPA03010350A MXPA03010350A MXPA03010350A MX PA03010350 A MXPA03010350 A MX PA03010350A MX PA03010350 A MXPA03010350 A MX PA03010350A MX PA03010350 A MXPA03010350 A MX PA03010350A MX PA03010350 A MXPA03010350 A MX PA03010350A
Authority
MX
Mexico
Prior art keywords
gatran
medicament
manufacture
treatment
pulmonary fibrosis
Prior art date
Application number
MXPA03010350A
Other languages
English (en)
Inventor
Kirk Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03010350A publication Critical patent/MXPA03010350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

De acuerdo con la invencion, se proporciona el uso de un gatran, tal como inogatran o melagatran, o un derivado farmaceuticamente aceptable del mismo, para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar.
MXPA03010350A 2001-05-18 2002-05-16 Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar. MXPA03010350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101762A SE0101762D0 (sv) 2001-05-18 2001-05-18 New use
PCT/SE2002/000950 WO2002094304A1 (en) 2001-05-18 2002-05-16 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis

Publications (1)

Publication Number Publication Date
MXPA03010350A true MXPA03010350A (es) 2004-03-16

Family

ID=20284164

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010350A MXPA03010350A (es) 2001-05-18 2002-05-16 Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar.

Country Status (14)

Country Link
US (1) US20040157772A1 (es)
EP (1) EP1395277A1 (es)
JP (1) JP2004529962A (es)
KR (1) KR20040000460A (es)
CN (1) CN1703234A (es)
BR (1) BR0209578A (es)
CA (1) CA2446049A1 (es)
IL (1) IL158809A0 (es)
MX (1) MXPA03010350A (es)
NO (1) NO20035102D0 (es)
NZ (1) NZ529345A (es)
SE (1) SE0101762D0 (es)
WO (1) WO2002094304A1 (es)
ZA (1) ZA200308632B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
IL158809A0 (en) 2004-05-12
EP1395277A1 (en) 2004-03-10
CN1703234A (zh) 2005-11-30
SE0101762D0 (sv) 2001-05-18
CA2446049A1 (en) 2002-11-28
JP2004529962A (ja) 2004-09-30
WO2002094304A1 (en) 2002-11-28
KR20040000460A (ko) 2004-01-03
BR0209578A (pt) 2004-06-22
NZ529345A (en) 2005-05-27
ZA200308632B (en) 2005-02-07
NO20035102D0 (no) 2003-11-17
US20040157772A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2004013120A8 (en) Novel benzodioxoles
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA03010761A (es) Combinaciones farmaceuticas.
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
MXPA04006041A (es) Antivirales de piridoquinoxalina.
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
IL143985A0 (en) New use of melagatran
MY136386A (en) New combination of a betablocker and a cholesterol-lowering agent
MXPA04005809A (es) Inhibidores de proteinas quinasas.
SE0200198D0 (sv) New use
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
MXPA03010350A (es) Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
WO2004035031A3 (en) Treatment of uveal melanoma
IL160486A0 (en) Citalopram for the treatment of elevated blood pressure
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
AU2002359762A1 (en) Luminacin analogs and uses thereof